Involving Creatine Phosphokinase Patents (Class 435/17)
  • Patent number: 10472665
    Abstract: The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: November 12, 2019
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Shigeru Ueda, Shinichi Sakasegawa
  • Patent number: 9989946
    Abstract: The invention relates to a program-controlled laboratory machine and to a method for the automatic program-controlled treatment of laboratory samples. The laboratory machine has a display having a first display area, via which program parameters that are required by the user are input, and has a second display area in which these input program parameters are shown. The performance of the treatment is effected automatically using the program parameters that are required by the user.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: June 5, 2018
    Inventors: Andreas Thieme, Claas Huesmann, Stefan Roth, Judith Lucke, Harald Pohl
  • Patent number: 9526345
    Abstract: Methods and compositions are provided where a transfected cell that produces a hybrid protein with a reporter-containing portion and a botulinum toxin cleavage site is contacted with a botulinum toxin at elevated temperatures and/or in media having a reduced sodium concentration. Kits that include such media and a botulinum toxin are also described.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: December 27, 2016
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Tim Piazza
  • Publication number: 20150093771
    Abstract: An analytical device for analysis of chemical or biological samples, a method of using such a device, based on rotation of the device, integrated sample dosing and optical detection, and a system comprising such a device are disclosed. The analytical device comprises a device body having a liquid processing unit. The liquid processing unit comprises a mixing chamber for mixing a sample with a reagent, a sample dosing chamber for delivering a defined volume of the sample to the mixing chamber, and a reagent channel for delivering the reagent to be mixed with the sample, wherein the mixing chamber also serves as a detection chamber.
    Type: Application
    Filed: December 2, 2014
    Publication date: April 2, 2015
    Inventors: Patrick Griss, Rainer Jaeggi, Goran Savatic, Vuk Siljegovic
  • Patent number: 8993313
    Abstract: Provided are an analytical instrument and an analytical method that allow for the direct analysis of a target substance in an undiluted specimen by a transmission photometry in a tightly closed cell container space. An analytical instrument is an analytical instrument for analyzing a target substance contained in a specimen flown in the tightly closed cell container by utilizing an oxidative color-developing agent and an oxidative enzyme reaction, in which an upper substrate and a lower substrate are arranged facing each other and at least a part of the upper substrate and/or at least a part of the lower substrate are/is made of a material transmitting light used for the analysis and having oxygen transmission properties.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: March 31, 2015
    Assignee: ARKRAY, Inc.
    Inventor: Toshihiro Imai
  • Publication number: 20140329262
    Abstract: This invention relates to a testing system for assessing the level of a biochemical marker, comprising a disposable device (2) with a sample inlet (4) and a at least one visible detection compartment (5A, 5B), arranged with composition including a chemical means (Y) for direct detection of said biochemical marker, wherein said composition also includes an inhibitor (Z) arranged to first detection compartment (5A) being arranged to block the biochemical marker up to a certain concentration.
    Type: Application
    Filed: November 22, 2012
    Publication date: November 6, 2014
    Inventors: Mathias Karlsson, Sofia Hiort Af Ornäs
  • Publication number: 20140206024
    Abstract: The present invention provides for stable nicotinamide adenine dinucleotide (NAD/NADH) and nicotinamide adenine dinucleotide phosphate (NADP/NADPH) derivatives of formula (I), enzyme complexes of these derivatives and their use in biochemical detection methods and reagent kits.
    Type: Application
    Filed: March 23, 2014
    Publication date: July 24, 2014
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Dieter Heindl, Joachim Hoenes, Carina Horn, Claudia Gaessler-Dietsche
  • Patent number: 8728751
    Abstract: The invention provides a method and a system for diagnosing lymphoma in cats. The system allows a care giver to measure the enzymatic activity of thymidine kinase in a blood sample. The invention teaches that when the enzymatic activity of thymidine kinase in the blood stream of a cat is above 15.5 Units per liter, the cat has a high probability of having lymphoma. The invention allows for initial diagnosis, follow up after treatment for lymphoma and/or monitoring for example in breeds that prone to have lymphoma.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: May 20, 2014
    Assignee: Veterinary Diagnostics Institute, Inc.
    Inventor: Randy Ringold
  • Patent number: 8697381
    Abstract: The present invention provides methods for identifying compounds that selectively and specifically modulate RGS21 gene expression, RGS21 protein expression, and/or the interaction of RGS21 with G proteins in taste signal transduction. In particular, the present invention provides methods for identifying modulators of RGS21 activity for enhancing sweet taste, or other taste perception. Compositions comprising modulators of RGS21 activity for modulating taste signaling transduction are also provided.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: April 15, 2014
    Assignee: The Coca-Cola Company
    Inventors: Harish Radhakrishna, Michael D. Brown, Grant Dubois
  • Publication number: 20130336953
    Abstract: The present invention relates to creatine kinase for use as a medicinal product or in the prevention or treatment of addictions or of addictive disorders associated with opiates, and to various other analytical uses or for filtration of creatine kinase.
    Type: Application
    Filed: February 3, 2012
    Publication date: December 19, 2013
    Applicants: UNIVERSITÉ DE STRABOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: Yannick Goumon, Alexis Laux - Biehlmann, Denise Stuber
  • Patent number: 8541190
    Abstract: Methods and materials use template-directed assembly of polypeptides and optionally additional reagents to analyze the functionality of membrane-associated proteins, such as, for example, portions of transmembrane proteins, membrane-associated proteins, and others proteins that bind to transmembrane proteins and membrane-associated proteins, and to analyze the effect of test compounds or mutations on the functionality of same. The methods and materials of the present application provide a more native-like environment for analyzing the functionality of membrane-associated proteins, and thus provide effective tools for studies involving the detection of the level of enzyme activity of such proteins in an environment that closely resembles the native environment in the cell, and for novel manufacturing processes.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: September 24, 2013
    Inventors: Robert M. Weis, Anthony L. Shrout, Edward A. Esposito
  • Publication number: 20130224728
    Abstract: A method for the production of 2-butanol by fermentation using a microbial production host is disclosed. The method employs a reduction in temperature during the fermentation process that results in a more robust tolerance of the production host to the butanol product.
    Type: Application
    Filed: April 15, 2013
    Publication date: August 29, 2013
    Applicant: BUTAMAX(TM) ADVANCED BIOFUELS LLC
    Inventor: BUTAMAX(TM) ADVANCED BIOFUELS LLC
  • Publication number: 20130196358
    Abstract: Subject of the invention is a method for the diagnosis of amyotrophic lateral sclerosis, comprising the steps of a) providing a sample from a patient, b) determining in the sample the level and/or activity of at least one marker, which is indicative of a glucose consumption disorder, c) comparing the level and/or activity to a known standard and d) deducing whether the patient has, or is susceptible to, amyotrophic lateral sclerosis.
    Type: Application
    Filed: May 11, 2011
    Publication date: August 1, 2013
    Inventor: Bert Steffan
  • Patent number: 8318449
    Abstract: It is intended to provide an assay method whereby the activity of a lipid-modifying enzyme can be conveniently measured over a wide range and a drug capable of controlling a lipid-modifying enzyme with the use of this assay method. The above problem can be solved by, for example, a method of measuring the activity of a lipid-modifying enzyme which comprises the steps of (I) preparing a lipid micelle containing a biotinylated lipid and a substrate for the lipid-modifying enzyme; (II) bringing the lipid micelle prepared in the above step (I) into contact with the lipid-modifying enzyme; and (III) evaluating the activity of the lipid-modifying enzyme by applying an evaluation method using the proximity effect to the product obtained in the above step (II).
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: November 27, 2012
    Assignee: Ajinomoto Co., Inc.
    Inventor: Naoyuki Fukuchi
  • Publication number: 20120270251
    Abstract: The invention provides a method of inhibiting the activity of a kinase or a synthetase, the method including binding an active site of the kinase or synthetase with a deuterated imidazole moiety, thereby inhibiting the activity of the kinase or the synthetase.
    Type: Application
    Filed: December 22, 2010
    Publication date: October 25, 2012
    Applicant: CSIR
    Inventors: Robyn Roth, Colin Peter Kenyon
  • Patent number: 8137985
    Abstract: A flow-through assay for detecting the quantity of an analyte residing in a test sample is provided. The flow-through assay contains a porous membrane that is in fluid communication with probe conjugates that contain a specific binding member and a detectable probe. The porous membrane also defines a detection zone and a calibration zone. The calibration zone contains a polyelectrolyte substantially non-diffusively immobilized on the porous membrane. The polyelectrolyte is capable of generating a detectable calibration signal that can be readily compared (visually, quantitatively, and the like) to a detection signal to determine the amount of analyte in the test sample.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: March 20, 2012
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Xuedong Song, Ning Wei, Curtis N. Sayre
  • Patent number: 8124368
    Abstract: The present invention relates to kinase sensors comprising a metal chelator and a fluorophore, where the chelator comprises a quinoline group and where the fluorophore is conjugated to the chelator. The invention also relates to methods of using these kinase sensors as well as kits comprising the kinase sensors.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: February 28, 2012
    Assignee: Life Technologies Corporation
    Inventor: Kyle Gee
  • Publication number: 20120021445
    Abstract: The present invention relates to methods of identifying, collecting and isolating pluripotent stem cells, and compositions of purified stem cells for the diagnosis of susceptibility to drug induced myopathy (DIM) and malignant hyperthermia (MH). Specifically, the present invention provides methods of producing skeletal muscle myocytes from patient-specific stem cells, and methods for identifying susceptibility to DIM and MH in patient-specific skeletal muscle myocytes generated from patient-specific stem cells. The present invention also relates to methods, compositions and kits for screening drugs for DIM and MH risk.
    Type: Application
    Filed: June 29, 2011
    Publication date: January 26, 2012
    Inventors: Kirk J. Hogan, Hector H. Valdivia, SR.
  • Publication number: 20120010095
    Abstract: The invention relates to diagnostic and prognostic assays and kits for pulmonary hypertension (PH) and types thereof. The invention includes detecting the expression level of markers associated with pulmonary hypertension for diagnosis, prognosis, or treatment of pulmonary hypertension.
    Type: Application
    Filed: June 1, 2011
    Publication date: January 12, 2012
    Inventors: Peter L. Jones, Darren Taichman
  • Publication number: 20120003677
    Abstract: Provided are methods of determining whether a cell in a tissue site is viable or nonviable. Also provided are methods of debriding tissue from a tissue site. Further provided are kits comprising a compound that distinguishes between viable and nonviable cells and instructions for using the compound on a tissue site. Additionally, the use of a compound that distinguishes between viable and nonviable cells is provided, where the use is to determine whether a cell in a tissue site is viable or nonviable. Also provided is a use of a compound that distinguishes between viable and nonviable cells, where the use is for the manufacture of the above-described kit.
    Type: Application
    Filed: September 13, 2011
    Publication date: January 5, 2012
    Inventors: Amy McNulty, Kristine Kieswetter, Todd Fruchterman
  • Publication number: 20110263438
    Abstract: The invention relates to a method for diagnosis and/or diabetic complications and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, wherein a determination of the marker procalcitonin (PCT: SEQ ID No. 1) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient under investigation. The invention further relates to a diagnostic device and a kit for carrying out said method.
    Type: Application
    Filed: February 3, 2011
    Publication date: October 27, 2011
    Inventor: Mehmet Ali Soylemez
  • Publication number: 20110251091
    Abstract: The invention relates to methods and kits for detecting thyroid cancer by detecting differences in the expression of genes that are differentially expressed in thyroid cancer cells.
    Type: Application
    Filed: September 11, 2009
    Publication date: October 13, 2011
    Applicant: Cornell University
    Inventors: Thomas J. Fahey, III, Nimmi Arora, Theresa Seognamiglio, Raymond K. Blanchard, Guozhen Liu
  • Patent number: 7939340
    Abstract: The invention relates to compositions, kits and methods used in hydroxyl radical detection. In some embodiments, the invention relates to compositions comprising a dye preferably methylene blue immobilized on a substrate. In additional embodiments, the invention relates methods of correlating color changes of a dye to the presence or absence of hydroxyl radicals. In some embodiments, the invention relates to a methylene blue dye containing test strip and its use in a method for detecting the presence of hydroxyl radicals.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: May 10, 2011
    Assignee: Board Of Trustees Of Michigan State University
    Inventors: Andrea Yuki Satoh, Susan J. Masten, James Trosko
  • Patent number: 7935493
    Abstract: The present invention provides protein fragment complementation assays for drug discovery, in particular to identify compounds that activate or inhibit cellular pathways. Based on the selection of an interacting protein pair combined with an appropriate PCA reporter, the assays may be run in high-throughput or high-content mode and may be used in automated screening of libraries of compounds. The interacting pair may be selected by cDNA library screening; by gene-by-gene interaction mapping; or by prior knowledge of a pathway. Fluorescent and luminescent assays can be constructed using the methods provided herein. The selection of suitable PCA reporters for high-throughput or high-content (high-context) assay formats is described for a diversity of reporters, with particular detail provided for examples of monomeric enzymes and fluorescent proteins.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: May 3, 2011
    Assignee: Odyssey Thera Inc.
    Inventors: Stephen William Watson Michnick, Ingrid Remy, Marnie MacDonald, Jane Lamerdin, Helen Yu, John K. Westwick
  • Patent number: 7927829
    Abstract: The present invention relates to a method for in vitro phosphorylation of TRAP derived from Staphylococcus aureus. In the present invention, the TRAP is first identified as a kinase that self-phosphorylates and is phosphorylated specifically in the presence of an oxidative metal ion such as iron, copper and zinc. Based upon this finding, a novel method for in vitro phosphorylation of purified TRAP is provided and also, a method for screening various chemicals and natural materials by using the above method is provided in order to select inhibitors against the TRAP phosphorylation. The inhibitors are expected to be applied for novel antibiotics of Staphylococcus aureus, because this TRAP phosphorylation is essential to infect Staphylococcus aureus. Therefore, the present invention can be widely used to develop novel drugs against Staphylococcus aureus and their resistant strains, in near future.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: April 19, 2011
    Assignee: Sungkyunkwan University Foundation for Corporate Collaboration
    Inventors: Kyeong Kyu Kim, Sung Wook Kang
  • Publication number: 20110053192
    Abstract: Disclosed herein is a dry fluorescence biosensor strip for rapid detection of a target analyte present in bodily fluids. The dry fluorescence biosensor strip comprises a sample receptacle and a dry detection membrane. The sample receptacle receives a sample of one of the bodily fluids. The dry detection membrane detects presence of the target analyte in the received sample based on fluorescence induced on the dry detection membrane. Fluorescent signals are emitted from the dry detection membrane on induction of fluorescence. A fluorometer quantifies measurable properties of the target analyte based on the emitted fluorescent signals. The dry fluorescence biosensor strip may further comprise a filtration membrane for filtering the received sample. The filtered sample migrates from the filtration membrane to the dry detection membrane. The dry detection membrane may then detect presence of the target analyte in the filtered sample.
    Type: Application
    Filed: November 10, 2010
    Publication date: March 3, 2011
    Inventor: Tom Cheng Xu
  • Patent number: 7824880
    Abstract: The present invention provides assays for detecting ADP, GDP and inorganic phosphate. These assays can be used directly to detect the presence of ADP, GDP and inorganic phosphate or can be used as part of a number of methods for identifying candidate agents that bind to a target protein or serve as modulators of the biological activity of a target protein.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: November 2, 2010
    Assignee: Cytokinetics
    Inventors: Ramesh Baliga, Donglin Guo, Daniel W. Pierce, Jeffrey T. Finer
  • Patent number: 7816099
    Abstract: An assay and kit for determining the activity of an enzyme such as kinase, ATPase and GTPase is disclosed. The assay and kit are useful in drug screening to select modulators of such an enzyme.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: October 19, 2010
    Assignee: Myrexis, Inc.
    Inventors: Kirill Ostanin, Thomas Hunsaker
  • Publication number: 20100255460
    Abstract: A device for biochemical processing and analysis of a measured sample volume of a sample is described. The device is characterised in that it consists of a sealed vessel (1) and that it comprises at least one thin pierceable membrane (2) through which a capillary tube (3) containing said measured sample volume of a sample can pass into said sealed vessel (1). Said sealed vessel (1) further contains at least one biochemically reactive substance (4) and a liquid (6). A method, wherein the device according to the invention is used for analysis, is also described.
    Type: Application
    Filed: October 24, 2008
    Publication date: October 7, 2010
    Inventors: Dario Kriz, Kirstin Kriz
  • Patent number: 7759085
    Abstract: A novel human kinase protein and nucleic acid molecule is disclosed. In addition to the isolated kinase protein, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: July 20, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Martin R. Hodge
  • Patent number: 7666617
    Abstract: The present invention relates to apparatus and methods for separating and detecting enzyme substrates using separation gels. For example, the apparatus and methods can be used to separate and detect kinase substrates for further analysis. The apparatus and methods can also be used to detect enzyme inhibitors, such as kinase inhibitors.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: February 23, 2010
    Assignee: University of Maryland, Baltimore County
    Inventors: Charles Bieberich, Xiang Li
  • Patent number: 7651841
    Abstract: A flow-through assay for detecting the quantity of an analyte residing in a test sample is provided. The flow-through assay contains a porous membrane that is in fluid communication with probe conjugates that contain a specific binding member and a detectable probe. The porous membrane also defines a detection zone and a calibration zone. The calibration zone contains a polyelectrolyte substantially non-diffusively immobilized on the porous membrane. The polyelectrolyte is capable of generating a detectable calibration signal that can be readily compared (visually, quantitatively, and the like) to a detection signal to determine the amount of analyte in the test sample.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: January 26, 2010
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Xuedong Song, Ning Wei, Curt Sayre
  • Patent number: 7635572
    Abstract: The present invention relates to methods of conducting assays for enzymatic activity on microarrays useful for the large-scale study of protein function, screening assays, and high-throughput analysis of enzymatic reactions. The invention relates to methods of using protein chips to assay the presence, amount, activity and/or function of enzymes present in a protein sample on a protein chip. In particular, the methods of the invention relate to conducting enzymatic assays using a microarray wherein a protein and a substance are immobilized on the surface of a solid support and wherein the protein and the substance are in proximity to each other sufficient for the occurrence of an enzymatic reaction between the substance and the protein. The invention also relates to microarrays that have an enzyme and a substrate immobilized on their surface wherein the enzyme and the substrate are in proximity to each other sufficient for the occurrence of an enzymatic reaction between the enzyme and the substrate.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: December 22, 2009
    Assignee: Life Technologies Corporation
    Inventors: Fang X. Zhou, Barry Schweitzer
  • Patent number: 7585644
    Abstract: The invention relates to a method of detecting the presence of mycoplasma in a test sample comprising: (i) providing a test sample; and (ii) detecting and/or measuring the activity of acetate kinase and/or carbamate kinase in the test sample, the activity being indicative of contamination by mycoplasma.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: September 8, 2009
    Assignee: Cambrex Bio Science Nottingham, Ltd.
    Inventors: Kevin John Slater, Anthony Pitt, Anne Cox, Sharon Patricia Mary Crouch
  • Publication number: 20090181413
    Abstract: This invention provides a method for differentially and simultaneously quantifying two target analytes via a single assay operation with the use of a single type of reagent in each of the two steps, i.e., the first step and the second step. In this method, the reaction product associated with the first target analyte is detected at an early stage of the second step and the reaction product associated with the second target analyte is then detected.
    Type: Application
    Filed: September 29, 2006
    Publication date: July 16, 2009
    Inventors: Yasuki Itoh, Keiko Matsumoto, Hiroshi Matsui, Yuhko Hirao
  • Publication number: 20090061418
    Abstract: The present invention generally relates to the determination of an analyte concentration (quantitative determination) or whether an analyte threshold level has been passed (qualitative determination) in a biological sample through employment of a disposable analytical microprocessor device. The device can include a batch-specific, self-executable algorithm for the calculation of the analyte concentration.
    Type: Application
    Filed: August 29, 2008
    Publication date: March 5, 2009
    Applicant: LIFEASSAYS AB
    Inventors: Dario KRIZ, Kristin Kriz
  • Publication number: 20090055974
    Abstract: Disclosed herein are nucleic acid molecules isolated from coffee (Coffea spp.) comprising sequences that encodes various sucrose metabolizing enzymes, along with their encoded proteins. Specifically, sucrose synthase, sucrose phosphate synthase and sucrose phosphatase enzymes and their encoding polynucleotides from coffee are disclosed. Also disclosed are methods for using these polynucleotides for gene regulation and manipulation of the sugar profile of coffee plants, to influence flavor, aroma, and other features of coffee beans.
    Type: Application
    Filed: August 16, 2006
    Publication date: February 26, 2009
    Applicant: CORNELL UNIVERSITY
    Inventors: Steven D. Tanksley, Chenwei Lin
  • Publication number: 20090047697
    Abstract: The present invention relates to a method for determining a risk whether an individual will suffer from a cardiovascular adverse event as a consequence of cardiac stress testing, comprising the steps of (a) measuring, preferably in vitro, the level of placenta growth factor, wherein (b) if the level of the placenta growth factor is at least increased, then the individual is at least at risk of suffering from an adverse event as a consequence of cardiac stress testing. In a further embodiment, additionally another marker is measured, particularly a natriuretic peptide, most particularly NT-proBNP. The present invention allows to stratify patients according to the environment and conditions under which cardiac stress testing should be carried out.
    Type: Application
    Filed: August 6, 2008
    Publication date: February 19, 2009
    Inventors: Georg Hess, Andrea Horsch
  • Publication number: 20090042228
    Abstract: Described are methods for diagnosing a cardiac disease, particularly an acute cardiac event, in a patient presenting with symptoms of acute cardiac decompensation, comprising the steps of (a) measuring, typically in vitro, the level of NT-proBNP (N-terminal brain natriuretic peptide) or a variant thereof in a sample from the patient, (b) measuring, typically in vitro, the level of NIT-proANP (N-terminal atrial natriuretic peptide) or a variant thereof in a sample from the patient, (c) combining the information of the measured levels of NT-proANP and NT-proBNP, wherein an increased level of NT-proANP in presence of a non-increased or weakly increased level of NT-proBNP indicates the presence of an acute cardiac event, or wherein an increased level of NT-proANP in presence of a highly increased level of NT-proBNP indicates the presence of a chronic cardiac disease. The methods also allow distinguishing an acute cardiac event from decompensation of a chronic cardiac disease.
    Type: Application
    Filed: November 27, 2007
    Publication date: February 12, 2009
    Inventors: Georg Hess, Andrea Horsch
  • Patent number: 7485434
    Abstract: In accordance with the present invention, it has been discovered that glucose and incretin hormones promote pancreatic islet cell survival via the calcium and cAMP dependent induction, respectively, of the transcription factor CREB. Specifically, a signaling module has been identified which mediates cooperative effects of calcium and cAMP on islet cell gene expression by stimulating the dephosphorylation and nuclear entry of TORC2, a cytoplasmic CREB coactivator. The module comprises a cAMP regulated snf1-like kinase called SIK2 and the calcium regulated phosphatase calcineurin, both of which associate with TORC2 in the cytoplasm. TORC2 is repressed under basal conditions through a phosphorylation dependent interaction with 14-3-3 proteins. cAMP and calcium signals stimulate CREB target gene expression via complementary effects on TORC2 dephosphorylation; cAMP disrupts TORC2-associated activity of SIK2 or related family members, whereas calcium induces TORC2 dephosphorylation via calcineurin.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: February 3, 2009
    Assignee: The Salk Institute for Biological Studies
    Inventor: Marc R. Montminy
  • Patent number: 7482134
    Abstract: The present invention relates to (a) a method for detecting a senescent cell, which comprises measuring a relative alteration to young cell in a signal or molecular species involved in signal transduction; (b) a method; and (c) a composition for modulating cellular senescence comprising treating a senescent cell with the effective amount of an inhibitor of adenylyl cyclase or an inhibitor of protein kinase A.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: January 27, 2009
    Assignee: Seoul National University Industry Foundation
    Inventors: Ik-Soon Jang, Eui-Ju Yeo, Sang-Chul Park
  • Patent number: 7470542
    Abstract: The present invention relates to the use of naturally occurring compounds and derivatives thereof as markers for predisposition of diabetes related diseases. The invention also relates to a pharmaceutical composition for treatment of the diabetes related diseases.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: December 30, 2008
    Assignee: Pride Proteomics A/S
    Inventors: Kurt Højlund, Stephen J. Fey, Peter Mose Larsen, Henning Beck-Nielsen, Krzysztof Wrzesinski
  • Patent number: 7449299
    Abstract: The present invention is directed to a quantum dot nanoparticle-based universal neurotoxin biosensor having three components (a) a dendrimer-encapsulated quantum dot nanoparticle; (b) acetylcholinesterase; and (c) an acceptor fluorophore, wherein the quantum dot nanoparticle and the acceptor fluorophore linked to the acetylcholinesterase.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: November 11, 2008
    Inventor: David Bauer
  • Patent number: 7416856
    Abstract: The present invention provides assays for detecting ADP, GDP and inorganic phosphate. These assays can be used directly to detect the presence of ADP, GDP and inorganic phosphate or can be used as part of a number of methods for identifying candidate agents that bind to a target protein or serve as modulators of the biological activity of a target protein.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: August 26, 2008
    Assignee: Cytokinetics, Inc.
    Inventors: Ramesh Baliga, Donglin Guo, Daniel W. Pierce, Jeffrey T. Finer
  • Patent number: 7378254
    Abstract: Described herein are methods which identify candidate agents as binding to a protein or as a modulator of the binding characteristics or biological activity of a protein. Generally, the methods involve the use of ADP or phosphate. The assays can be used in a high throughput system to obviate the cumbersome steps of using gels or radioactive materials.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: May 27, 2008
    Assignee: Cytokinetics
    Inventors: Jeffrey T. Finer, Fady Malik, Roman Sakowicz, Christopher Shumate, Kenneth Wood
  • Patent number: 7376117
    Abstract: Interleaving circuit for a multiband OFDM (orthogonal frequency division multiplexing) transceiver of a ultra wide band wireless personal access network transmitting OFDM modulated symbols, wherein each OFDM symbol consists of a predetermined number (NCBPS) of encoded bits, said interleaving circuit comprising a symbol interleaving unit which receives an input bitstream of encoded bits and permutes adjacent bits of said input bitstream across different OFDM symbols; an intra-symbol tone interleaving unit which receives the bits permuted by said symbol interleaving unit and permutes adjacent bits of each OFDM symbol across uncorrelated data sub-carriers; and an intra-symbol cyclic shift unit which shifts cyclically NCBPS bits of each OFDM symbol in response to a shift value (K) which is changed between adjacent OFDM symbols.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: May 20, 2008
    Assignee: Infineon Technologies AG
    Inventors: Yossi Erlich, Assaf Gurevitz
  • Patent number: 7368258
    Abstract: The present invention relates to apparatus and methods for separating and detecting enzyme substrates using separation gels. For example, the apparatus and methods can be used to separate and detect kinase substrates for further analysis. The apparatus and methods can also be used to detect enzyme inhibitors, such as kinase inhibitors.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: May 6, 2008
    Assignee: University of Maryland, Baltimore County
    Inventors: Charles Bieberich, Xiang Li
  • Patent number: 7338775
    Abstract: An assay and kit for determining the activity of an enzyme such as kinase, ATPase and GTPase is disclosed. The assay and kit are useful in drug screening to select modulators of such an enzyme.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: March 4, 2008
    Assignee: Myriad Genetics, Inc.
    Inventors: Kirill Ostanin, Thomas Hunsaker
  • Patent number: 7317038
    Abstract: To provide a semaphorin inhibitor; a peripheral or central nerve regeneration promoter which contains said semaphorin inhibitor as an active ingredient; and a preventive or remedy for a neuropathic disease and a neurodegenerative disease containing said nerve regeneration promoter, or the like. A low-molecular weight compound, which acts at a concentration of 10 ?g/ml or below to inhibit the growth cone collapse activity of semaphorin such as semaphorin 3A, semaphorin 6C or the like and/or the nerve outgrowth inhibitory activity of semaphorin in a collagen gel and which does not substantially affect cell proliferation, is obtained from the culture of strain SPF-3059 belonging to the genus Penicillium. The low-molecular weight compound with the semaphorin inhibitory activity thus obtained exhibits the in vivo nerve-regeneration promoting action.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: January 8, 2008
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toru Kimura, Kaoru Kikuchi, Kazuo Kumagai, Nobuo Hosotani, Akiyoshi Kishino
  • Patent number: 7244761
    Abstract: To provide a semaphorin inhibitor; a peripheral or central nerve regeneration promoter which contains said semaphorin inhibitor as an active ingredient; and a preventive or remedy for a neuropathic disease and a neurodegenerative disease containing said nerve regeneration promoter, or the like. A low-molecular weight compound, which acts at a concentration of 10 ?g/ml or below to inhibit the growth cone collapse activity of semaphorin such as semaphorin 3A, semaphorin 6C or the like and/or the nerve outgrowth inhibitory activity of semaphorin in a collagen gel and which does not substantially affect cell proliferation, is obtained from the culture of strain SPF-3059 belonging to the genus Penicillium. The low-molecular weight compound with the semaphorin inhibitory activity thus obtained exhibits the in vivo nerve-regeneration promoting action.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: July 17, 2007
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Toru Kimura, Kaoru Kikuchi, Kazuo Kumagai, Nobuo Hosotani, Akiyoshi Kishino